Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with chronic mitral valve disease

Jung Kook Kim, Jun Seok Park, Kyoung Won Seo, Kun Ho Song

Research output: Contribution to journalArticle

Abstract

Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.

Original languageEnglish (US)
Pages (from-to)35-38
Number of pages4
JournalJournal of Veterinary Clinics
Volume35
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Keywords

  • Cardiac biomarker
  • CMVD
  • Level
  • NT-proBNP
  • ST2

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with chronic mitral valve disease'. Together they form a unique fingerprint.

  • Cite this